Catalyst Pharmaceutical Partners Announces Commencement Of CPP-109 Investigator-Sponsored Study In Patients With Treatment Refractory Tourette's Disorder

Patrick J. McEnany, Catalyst's Chief Executive Officer, commented, "We are very pleased to provide support to Mount Sinai School of Medicine on this important proof-of-concept study. We look forward to seeing the initial interim results early next year and we hope they will support moving forward with our patent applications."

About Tourette's Disorder

Marked by involuntary vocal sounds and physical movements called tics, Tourette's Disorder is an inherited neuropsychiatric condition frequently misunderstood and misdiagnosed, affecting around 200,000 Americans, mostly children and adolescents. Orphan drug designation has been granted to several products intended to treat patients diagnosed with this disorder. The Company intends to pursue such designation should the results of the trial support the potential efficacy of vigabatrin for this indication.

About Catalyst Pharmaceutical Partners

Catalyst Pharmaceutical Partners, Inc. is a development-stage specialty pharmaceutical company focused on the development and commercialization of prescription drugs targeting diseases and disorders of the central nervous system. Catalyst has two products in development and is currently evaluating its lead product candidate, CPP-109 (vigabatrin, a GABA aminotransferase inhibitor), for the treatment of cocaine addiction. CPP-109 has been granted "Fast Track" status by the U.S. Food & Drug Administration (FDA) for the treatment of cocaine addiction. Catalyst also expects to evaluate CPP-109 for the treatment of other addictions. Catalyst is also developing CPP-115, another GABA aminotransferase inhibitor that is more potent than vigabatrin and has reduced side effects (e.g., visual field defects, or VFDs) from those associated with vigabatrin. Catalyst is planning to develop CPP-115 for several indications, including drug addiction, epilepsy and for use in other selected central nervous system indications. CPP-115 has been granted orphan drug designation for the treatment of infantile spasms by the FDA. Catalyst believes that it controls all current intellectual property for drugs that have a mechanism of action related to the inhibition of GABA aminotransferase. For more information about the Company, go to http://www.catalystpharma.com .

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties which may cause the Company's actual results in future periods to differ materially from forecasted results. A number of factors, including the anticipated timing of the results from the clinical study described in this press release, whether the study will be successful, whether CPP-109 will ultimately be determined to be effective in treating substance abuse, whether the patent application described in this press release will ever be approved, and the other factors described in the Company's filings with the U.S. Securities and Exchange Commission (SEC), could adversely affect the Company. Copies of the Company's filings with the SEC are available from the SEC, may be found on the Company's website or may be obtained upon request from the Company. The Company does not undertake any obligation to update the information contained herein, which speaks only as of this date.

CONTACT: Patrick J. McEnany
         Catalyst Pharmaceutical Partners
         Chief Executive Officer
         [phone]
         [e-mail]
         
         Melody Carey
         Rx Communications Group
         Co-President
         [phone]
         [e-mail]

« First ‹ Previous 1 2